Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
about
Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.Efficacy and Toxicity of Low-Dose versus Conventional-Dose Chemotherapy for Malignant Tumors: a Meta-Analysis of 6 Randomized Controlled TrialsClinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study.The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.miR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression.Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study.RAD51B as a potential biomarker for early detection and poor prognostic evaluation contributes to tumorigenesis of gastric cancer.Esophagogastric Adenocarcinoma: Is More Chemotherapy Better?MiR-33b-5p sensitizes gastric cancer cells to chemotherapy drugs via inhibiting HMGA2 expression.Gastric Adenocarcinoma: A Multimodal Approach.Enhanced antiproliferative activity of antibody-functionalized polymeric nanoparticles for targeted delivery of anti-miR-21 to HER2 positive gastric cancer.Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma.Management and survival analysis of elderly patients with a cancer in the digestive system who refused to receive anticancer treatments.Current therapeutic landscape for advanced gastroesophageal cancers.Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna.Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer.Optimal Collaborative Management of Patients With Esophagogastric Cancers.Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis.Eastern Canadian Colorectal Cancer Consensus Conference 2017
P2860
Q33436548-D6EEDBA3-E8CD-4ED9-A2DF-EB9773D8F4DFQ33440431-E0DC2776-939D-42C4-8506-62EAFA1FB60BQ33605930-78F87A14-19CA-4336-BC5B-6253E816D891Q33660069-4421DFA6-F926-44BB-86FB-B2A71FF47471Q37376531-04E08D71-02FF-4095-9DDD-80FC4EC9C741Q37392967-561E2259-031D-4C04-97B2-EEED7C8297B0Q37644000-C4B00956-811B-437A-B0A9-2CAB7C2F2F7DQ38744610-CC048E1D-4CF1-4AFB-8EAE-CB86201E4D87Q38794776-CF1C40F7-3431-4847-BBC0-B3A9FDDAE8A1Q38823432-E7F947F1-00DF-48EE-A42F-27C0F0750E56Q41221377-E5C3523B-F728-467F-99B0-5A58876367E9Q42366537-0EF69DA9-FEBE-469C-99E7-3CE9812176C6Q47141588-DC536E6F-1223-440B-9DF6-6F0082A7332CQ47402625-90030B63-CC73-49FB-9807-2A6A826A7DC9Q47739682-68EE517B-FB2C-44F7-BF28-954F56A5F848Q50054472-D0D69DC0-6069-41EC-8B0F-5D7FF584A2B3Q52581752-EF99B4F7-CD5B-4579-B078-9C1016218214Q54970742-95F859EB-9439-49DD-AA45-F9CDF8BF6933Q55017077-87BA6E5A-D673-49DF-A0B7-03A46E55E2DDQ55155589-BA311068-5D66-4168-96B9-5DF130C95ED8Q55280819-4C72D317-DC25-4BEE-85C8-7BBBE4CD6AA7Q55516981-36A46D7D-EE25-49E7-BD79-E488A2A99A02Q58783221-158F3438-7B5B-41E9-8360-B41AA0800696
P2860
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Randomized Multicenter Phase I ...... US Gastric Cancer Consortium.
@en
type
label
Randomized Multicenter Phase I ...... US Gastric Cancer Consortium.
@en
prefLabel
Randomized Multicenter Phase I ...... US Gastric Cancer Consortium.
@en
P2093
P356
P1476
Randomized Multicenter Phase I ...... US Gastric Cancer Consortium.
@en
P2093
Allyson Ocean
Bhoomi Mehrotra
Charles Henderson
David P Kelsen
Manish A Shah
Margaret Kemeny
Marinela Capanu
Paul Ritch
Ronald Stoller
Smitha Krishnamurthi
P304
P356
10.1200/JCO.2015.60.7465
P407
P577
2015-10-05T00:00:00Z